An Open-Label, Single Center, Nonrandomized, Dose-Escalation Phase 1 Study to Evaluate Safety and Tolerability of SHR-1210 in Subjects With Advanced Solid Tumor
Phase of Trial: Phase I
Latest Information Update: 22 Jan 2018
At a glance
- Drugs Camrelizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 22 Jan 2018 Results (n=30) assessing safety, efficacy and biomarkers of SHR-1210, an anti-PD-1 antibody, in patients with recurrent or metastatic ESCC, were published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 06 Jun 2017 Results (n=58) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 14 Dec 2016 Planned number of patients changed from 36 to 96.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History